Intellia Therapeutics (NTLA) PT Raised to $20 at Wedbush, Following Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $12.47 --0%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 18 | New: 15
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 18 | New: 15
Join SI Premium – FREE
Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $20.00 (from $16.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Upgrades CrowdStrike (CRWD) to Buy, 'investors are still not fully appreciating the extent to which AI will expand the market for cybersecurity'
- HSBC Holdings Plc. (5:HK) (HSBC) PT Lowered to GBP185 at JPMorgan
- Goldwind - A (002202:CH) (XJNGF) PT Lowered to HK$15 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
